Evidence map›Paper›PMID 39057154›Full record

ArticleCurrent oncology (Toronto, Ont.)2024

BRCA Testing for Patients Treated in Italy: A National Survey of Breast Centers Associated with Senonetwork.

Corrado Tinterri, Damiano Gentile, Francesco Caruso, Laura Cortesi, Michelino De Laurentiis, Lucio Fortunato, Donatella Santini, Daniela Turchetti, Alberta Ferrari, Alberto Zambelli and 1 more

Abstract read
In one paragraph

Article in Current oncology (Toronto, Ont.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Cancers · 2025
    Article
  5. Cancers · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Corrado TinterriBreast Unit, IRCCS Humanitas Research Hospital, Via Manzoni 56, 20089 Milan, Italy.
Damiano GentileBreast Unit, IRCCS Humanitas Research Hospital, Via Manzoni 56, 20089 Milan, Italy.ORCID 0000-0002-8861-5223
Francesco CarusoHICC Humanitas Istituto Clinico Catanese, 95045 Misterbianco, Italy.
Laura CortesiAzienda Ospedaliera-Universitaria di Modena, Università degli Studi di Modena e Reggio Emilia, 41121 Modena, Italy.ORCID 0000-0001-8950-8561
Michelino De LaurentiisDipartimento di Oncologia Senologica, Istituto Nazionale Tumori "Fondazione PASCALE", 80131 Napoli, Italy.ORCID 0000-0001-9009-1572
Lucio FortunatoBreast Centre, Azienda Ospedaliera San Giovanni-Addolorata, 00184 Rome, Italy.
Donatella SantiniIRCCS Azienda Ospedaliero, Universitaria di Bologna Policlinico di Sant'Orsola, 40138 Bologna, Italy.ORCID 0000-0002-1692-6348
Daniela TurchettiDepartment of Medical and Surgical Sciences, University of Bologna, 40138 Bologna, Italy.
Alberta FerrariFondazione IRCCS Policlinico San Matteo di Pavia, 27100 Pavia, Italy.ORCID 0000-0003-2525-3787
Alberto ZambelliDepartment of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20072 Milan, Italy.ORCID 0000-0002-1374-1831
Senonetwork Italia Breast Centre Responders

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBreast units (BUs) provide breast cancer (BC) care, including prevention, treatment, and genetic assessment. Genetic research has highlighted BRCA1/2 mutations as key hereditary BC risk factors. BRCA testing is crucial for personalized treatment and prevention strategies. However, the integration of BRCA testing in Italian BUs faces multiple challenges. This study, by Senonetwork Italia, aimed to evaluate genetic testing practices and identify obstacles within Italian BUs.

methodsSenonetwork Italia conducted a 16-question web-based survey involving 153 BUs. The survey assessed aspects of BRCA testing, including timing, urgency, counseling, patient selection, and multi-gene panels.

resultsOf the 153 BUs, 109 (71.2%) responded. Testing before surgery was performed by 70.6% of centers, with urgent cases acknowledged by 87.2%. Most centers (56.0%) arranged urgent pre-test counseling within a week. BRCA mutation status influenced treatment decisions in 99.1% of cases. Multi-gene panels were used by 33.0% of centers for all genetic counseling cases, while 56.0% followed standard referral criteria. The main challenges included cost, reimbursement, and reporting timelines.

conclusionsThis survey highlights significant variations in BRCA testing practices across Italian BUs and identifies key logistical and financial challenges. There is a need for standardized practices of genetic testing to ensure personalized and effective BC management in Italy.

Indexed as

Breast NeoplasmsGenetic TestingBRCA1 ProteinBRCA2 ProteinFemaleGenetic CounselingHumansItalyMutationSurveys and QuestionnairesBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, humanBRCA testingbreast cancergenetic counseling

Identifiers

PMID39057154
PMCPMC11276301

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.